These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6126136)

  • 1. [Drug treatment in the elderly: special aspects of diuretics (author's transl)].
    Mühlberg W; Platt D
    Aktuelle Gerontol; 1982 Jul; 12(4):134-8. PubMed ID: 6126136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [On the bioavailability of hydrochlorothiazide and triamterene from commercial drugs (author's transl)].
    Knauf H; Möhrke W; Mutschler E; Völger KD
    Arzneimittelforschung; 1980; 30(6):1001-4. PubMed ID: 7191258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of triamterene and its active metabolites in renal insufficiency (author's transl)].
    Grebian B; Geissler HE; Knauf H; Mutschler E; Schnippenkoetter I; Völger KD; Wais U
    Arzneimittelforschung; 1978; 28(8):1420-5. PubMed ID: 582410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
    Bartle WR; Coates PE; Fisher MM; Louman FJ
    Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS.
    Dong H; Xu F; Zhang Z; Tian Y; Chen Y
    J Mass Spectrom; 2006 Apr; 41(4):477-86. PubMed ID: 16541392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
    Sandall JM; Millership JS; Collier PS; McElnay JC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
    Platt D; Abshagen U; Mühlberg W; Horn HJ; Schmitt-Rüth R; Vollmar J
    Arch Gerontol Geriatr; 1984 Jul; 3(2):147-59. PubMed ID: 6476975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics of xipamide and triamterene in healthy probands].
    Diembeck W; Dies R; Heinz N
    Arzneimittelforschung; 1982; 32(11):1482-5. PubMed ID: 6891256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bioavailability studies of two spironolactone-preparations (author's transl)].
    Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
    Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
    Vergin H; Nuss U; Strobel K
    Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biological availability of spironolactone in two different galenic forms (author's transl)].
    Rameis H; Hitzenberger G; Horwatitsch H
    Dtsch Med Wochenschr; 1979 Jun; 104(24):881-3. PubMed ID: 446311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Studies on the possible correlations between in vitro and in vivo data using commercial triamterene formulations (author's transl)].
    Stüber W; Mutschler E; Steinbach D
    Arzneimittelforschung; 1980; 30(7):1158-63. PubMed ID: 7191300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V; Martens H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):334-40. PubMed ID: 9266289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
    Steimer W; Müller C; Eber B
    Clin Chem; 2002 Mar; 48(3):507-16. PubMed ID: 11861441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group.
    McClennen W; Wilson T
    Clin Invest Med; 1998 Jun; 21(3):142-50. PubMed ID: 9627768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of diuretics in geriatric patients.
    Mühlberg W
    Arch Gerontol Geriatr; 1989; 9(3):283-90. PubMed ID: 2640087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of spironolactone metabolites in plasma and target organs of guinea pigs.
    Los LE; Coddington AB; Ramjit HG; Colby HD
    Drug Metab Dispos; 1993; 21(6):1086-90. PubMed ID: 7905388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.